Effects of Pneumococcal, Influenza Vaccines on COPD Exacerbations

The number of acute exacerbations, hospitalizations, ICU admissions, invasive mechanical ventilation, and mortality were analyzed in the study for 146 patients with spirometry-confirmed COPD.

This article is written live from ID Week 2017 Annual Meeting in San Diego, CA. MPR will be reporting news on the latest findings from leading experts in infectious diseases. Check back for more news from IDWeek 2017.

SAN DIEGO—Influenza and pneumococcal vaccine are associated with lower risks of chronic obstructive airway disease (COPD) exacerbations, hospitalizations, and ICU admissions, according to a prospective study of 146 COPD patients with reported at IDWeek 2017.

“Overall, there was significantly lesser number of exacerbations, hospitalizations, ICU admissions, requirement of mechanical ventilation and mortality among vaccinated group as compared to controls,” the team reported in a poster presentation.

Subgroup analysis showed a significant benefit from vaccination in COPD, they concluded.

Respiratory bacterial and viral infections commonly cause COPD exacerbations. The study findings bolster the case that the influenza vaccine and pneumococcal vaccines decrease the risk of such exacerbations.

The number of acute exacerbations, hospitalizations, ICU admissions, invasive mechanical ventilation, and mortality were analyzed for 146 patients with spirometry-confirmed COPD (using GOLD criteria) for 1 year following influenza and pneumococcal polysaccharide vaccine, and outcomes were compared to those for 146 unvaccinated control-group patients.

“In the vaccinated group there was statistically significant reduction in number of exacerbations of COPD, requirement of hospitalization, ICU admissions and mortality,” they reported. Subgroup analysis revealed fewer hospitalizations, ICU admissions and deaths among vaccinated patients than matched controls.

Vaccinated and unvaccinated patients experienced a median of 3.23 and 4.5 exacerbations, respectively (odds ratio [OR] 0.35; 95% CI: 0.22–0.57; P<0.001). Hospitalizations and ICU admissions occurred in 36.3% vs. 50% and 17.8% vs. 30.1% of vaccinated and unvaccinated patients, respectively (ORs: 0.57 and 0.5; P=0.018 and 0.013, respectively). Fourteen percent of vaccinated patients and 6% of unvaccinated patients required mechanical vaccination (OR 0.37; 95% CI: 0.16–0.83; P=0.014), they reported.

Three vaccinated patients and 17 unvaccinated patients died (OR 0.21; 95% CI: 0.07–0.65; P=0.003).

For continuous infectious disease news coverage from the IDWeek 2017, check back to MPR’s IDWeek page for the latest updates.


Haque A, Ameer A, Ananthanarayanan R, Padmanabhan A. Efficacy of Influenza and Pneumococcal Vaccination In Preventing COPD Exacerbation. Poster presented at IDWeek; October 4–8, 2017; San Diego, CA. http://www.idweek.org.